Ipamorelin dosage, as the research recorded it — doses, routes, and a ~2-hour half-life, reported third person.

Read this first

This page describes ipamorelin dosage the way the studies recorded it — which doses were given to which animals or volunteers, by which route, and for how long. It is not a how-to and not a recommendation. Ipamorelin is not an approved medicine, and there is no established human dose; the numbers below are research figures, written in the third person.

The one solid human pharmacokinetic fact is the half-life: about 2 hours after intravenous dosing in healthy volunteers, with a single growth-hormone pulse peaking near 40 minutes ^[2]. Most efficacy work is in rodents, given under the skin (subcutaneous) or into the vein (intravenous). Community protocols that pair ipamorelin with CJC-1295 by subcutaneous injection have no peer-reviewed human dosing basis at all — they are described here as anecdotal context, not as anything to follow.

Doses studied, by species and route

The published doses span a wide range because they served different experimental questions. The human PK/PD study used single intravenous infusions of 4.21–140.45 nmol/kg over 15 minutes ^[2]. The human Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days ^[3]. The rat bone-growth study used 18, 90, and 450 µg/day subcutaneously, divided three times daily ^[4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally ^[5].

Routes that have been studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (the dominant route in rodent body-composition work and in community use), intranasal (rodent PK, roughly 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable — only engineered ipamorelin-derived analogs achieved meaningful oral absorption, and only in animals, which the ipamorelin oral page covers in full.

How much cjc-1295 ipamorelin should i take

There is no answer to "how much cjc-1295 ipamorelin should i take" that comes from controlled human evidence, because the combination has never been dosed in a controlled human trial for any outcome ^[3]. This site does not provide a human dose for either peptide. What the literature offers is research context: ipamorelin's human work used intravenous infusions and a 0.03 mg/kg IV trial dose ^[2][3], and CJC-1295's single-agent human study used 30–60 µg/kg subcutaneously ^[10]. Subcutaneous "stack" regimens circulating in communities have no peer-reviewed human dosing basis.

Half-life and pharmacokinetics

Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes (0.67 h) post-dose, not a sustained elevation ^[2]. In rats, plasma clearance is roughly five-fold lower than that of GHRP-6, indicating greater metabolic stability within the class. The short half-life and discrete-pulse pharmacodynamics are central to why GH secretagogues are studied as pulsatile rather than continuous signals.

Handling and stability of research material

Ipamorelin is supplied as a lyophilized (freeze-dried) powder — either the free base or the acetate salt — and reconstituted with bacteriostatic water for research handling. As a peptide, it is subject to degradation by heat and by repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature; they describe how research material behaves, not a clinical preparation instruction.

How to reconstitute cjc-1295 ipamorelin 5mg

Questions like "how to reconstitute cjc-1295 ipamorelin 5mg" come up because these peptides ship as lyophilized powder that must be dissolved before use. As general research-handling context: lyophilized peptide is reconstituted with bacteriostatic water, kept refrigerated, and protected from heat and repeated freeze-thaw to limit degradation. This site does not provide a preparation protocol for human use — ipamorelin is not an approved medicine and no human dosing pathway is described here. The note is provenance for how research-grade material is handled, nothing more.